~~<i id='8E73D2DA7C'><strike id='8E73D2DA7C'><tt id='8E73D2DA7C'><pre id='8E73D2DA7C'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

focus

author：Wikipedia 2025-10-01 00:48:49 - browse：62

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： 10 reasons why health care startups fail

hotspot

entertainment

NewresearchledbyStanfordneuro-oncologistMichelleMonjeshineslightontheelectrochemicalsignalingpathway

WSS

Biogen walks away from Aduhelm, years after polarizing approval

Live blog: Hearing on CRISPR

Zyn nicotine pouches become unlikely player in latest culture war

Bill would allow buprenorphine prescription for addiction via telehealth

Medicare drug price negotiation legal challenge met with skepticism

DeepMind touts AlphaFold's new skills as protein folding AI models face off

explore

focus

hotspot

Psychedelics group wrestles with new pharma identity

Syphilis numbers in the United States reach record heights

Medical leaders decry Supreme Court decision on affirmative action

Merck CEO won’t testify in Senate, citing no expertise in drug prices

Continuity nursing helped my family in our darkest PICU moments

Venture capital firm's plans to take over Akron hospital face hurdles

Duchenne breakthrough therapy leaves behind pioneering families

Sarepta Duchenne therapy fails to meet primary endpoint in trial

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

What is microchimerism and how does it affect maternal health?

hotspot

Health Care Service Corp to buy Cigna Medicare Advantage plans

How neuroscience research could help beat back brain cancer

Bill would allow buprenorphine prescription for addiction via telehealth

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

Sarepta Duchenne therapy fails to meet primary endpoint in trial

Vertex non

hotspot

hotspot

hotspot

entertainment